VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
FOCL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
FOCLEDAP TMS S.A. American Depositary Shares
$2.84$124M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksFOCLBalance Sheet

EDAP TMS S.A. American Depositary Shares (FOCL) Balance Sheet

29Y historyFree accessUpdated daily

Total debt surged 18-fold from $2.3M in 2026Q1 to $41.7M in 2026Q2, driving equity to -$3.2M against a -$152.2M retained earnings deficit, while cash fell 69% from $38.4M to $11.8M over the ten-quarter period.

Income StatementBalance SheetCash FlowRatios

FOCL Balance Sheet

Annual statement

FOCL Balance Sheet

EDAP TMS S.A. American Depositary Shares (FOCL) balance sheet — 29-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97
Total Current Assets94.78M57.16M72.36M86.69M96.61M76.63M55.54M47.25M46.16M47.52M42.72M33.04M26.55M22.17M24.73M27.05M29.86M33.25M35.79M36.18M26.39M22.76M22.02M25.83M34.12M46.01M39.99M23.97M33.34M40.45M
Cash & Short-Term Investments56.27M20.45M30.9M48.02M67.38M53.66M30.22M23.44M22.25M24.02M23.19M14.58M12.14M7.68M8.08M6.47M8.89M12.7M14.97M18.64M10.93M8.31M9.39M10.41M15.85M29.1M25.11M3.27M8.78M11.73M
Cash Only56.27M20.45M30.9M48.02M67.38M53.66M30.22M23.44M22.25M24.02M23.19M13.58M11.14M6.68M7.04M4.9M7.37M11.59M13.83M17.55M9.89M8.31M9.39M10.41M15.77M19.39M3.4M3.27M8.78M11.73M
Short-Term Investments000000000001M1M1M1.04M1.57M1.52M1.11M1.14M1.09M1.03M00081.95K9.7M21.71M000
Accounts Receivable11.78M22.58M21.01M21.25M15.95M13.78M15.1M14.13M15.22M14.82M10.57M10.74M8.14M9.39M11.15M13.96M16.09M15.53M15.56M12.04M10.87M9.61M8.19M9.4M11.21M10.85M8.68M11.46M14.92M17.18M
Days Sales Outstanding94.15116.51110.56118.74100.596.58116.02102.59120.21134.1697.98121.59110.95142.37156.11228.51247.73227.71246.39196.58195.85168.71134.96186.11204.72165.02115.93218.3234.83191.63
Inventory8.33M12.83M19.15M16.69M12.57M8.53M9.77M9.18M8.24M8.09M8.47M6.15M5.91M4.7M4.26M3.92M3.92M3.79M4.02M4.31M3.77M4.45M3.94M5.26M6.57M5.61M5.61M8.53M8.61M7.18M
Days Inventory Outstanding118.59115.2172.06156.5141.23102.7134.42125.21114.56125.07145.55121.57138.37116.1799.54106.5100.3197.43105.22119.54115.06131.93105.13146.82208.33134.5143.78288.88271.07161.99
Other Current Assets18.41M000003500.63K436.69K002.07M42K23K32K57K969K1.23M1.23M715.29K84.1K076.72K331.11K106.73K113.51K242.76K707.58K1.02M4.36M
Total Non-Current Assets15.93M21.83M16.76M14.44M11.32M11.19M11.99M12.31M9.56M8.79M6.42M5.54M5.54M4.75M5.72M5.5M6.07M7.13M8.08M8.89M6.08M6.01M5.86M6.03M5.7M7.2M10.43M12.49M12.02M10.45M
Property, Plant & Equipment10.41M13.5M10.7M9.05M6.39M5.88M6.85M7.54M4.81M4.42M2.92M2.12M2.12M1.66M2.04M2.53M2.88M3.29M3.76M4.19M3.21M3.13M2.8M2.9M1.99M2.24M1.83M3.1M1.71M2.82M
Fixed Asset Turnover5.51x5.24x6.48x7.22x9.07x8.86x6.93x6.67x9.61x9.12x13.48x15.19x12.62x14.55x12.81x8.80x8.24x7.57x6.13x5.34x6.31x6.65x7.90x6.36x10.06x10.73x14.93x6.19x13.60x11.61x
Goodwill732K2.83M2.5M2.66M2.57M2.74M2.95M2.71M2.76M2.9M2.54M2.41M2.41M2.41M2.41M2.41M2.41M2.41M2.41M2.42M2.41M2.41M00000000
Intangible Assets1.82M1.8M1.12M1.2M772.69K827.88K931.12K864.33K968.25K632.82K157.16K39K24K37K72K68K82K103K102K78.88K71.22K86.12K2.53M2.58M2.64M2.52M2.73M5.09M5.71M6.45M
Long-Term Investments2.57M546K000002.25K29.72K92.46K315.37K593K000000000000000000
Other Non-Current Assets2.7M2.06M1.57M719.13K700.12K720.99K801.43K717.28K625.3K552.37K471.47K969K982K647K1.2M484K702K1.33M1.8M2.21M386.42K390.07K522.28K547.09K1.07M2.44M5.88M4.31M4.6M1.18M
Total Assets110.72M79M89.12M101.13M107.92M87.82M67.53M59.57M55.72M56.31M49.14M38.58M32.15M26.87M30.44M32.55M35.94M40.38M43.86M45.07M32.47M28.77M27.88M31.85M39.82M53.21M50.43M36.46M45.36M50.91M
Asset Turnover0.75x0.90x0.78x0.65x0.54x0.59x0.70x0.84x0.83x0.72x0.80x0.84x0.83x0.90x0.86x0.68x0.66x0.62x0.53x0.50x0.62x0.72x0.79x0.58x0.50x0.45x0.54x0.53x0.51x0.64x
Asset Growth %24.02%-11.36%-11.88%-6.3%22.89%30.05%13.37%6.91%-1.06%14.59%-19.99%19.65%-11.73%-6.47%-9.43%-11%-7.95%-2.69%38.8%12.86%3.2%-12.47%-20.01%-25.16%5.51%38.3%-19.62%-10.9%-
Total Current Liabilities36.07M37.14M39.15M30.48M23.17M20.41M26.31M19.64M19.22M19.37M15.83M16.27M12.16M11.59M13.12M20.7M14.66M15.18M14.46M12.9M10.93M9.87M8.27M10.99M9.82M11.94M10.21M13.99M13.56M13.36M
Accounts Payable011.78M13.06M12.41M7.09M6.27M6.98M6.79M7.2M7.58M6.29M6.1M5.5M5.43M5.82M5.72M4.31M4.06M5.07M5.07M3.99M3.53M2.91M3.15M4.2M5.45M4.42M4.9M3.33M5.09M
Days Payables Outstanding116.95105.8117.33116.3679.6175.4796.0492.57100.02117.1108.03120.52128.94134.39135.89155.54110.35104.29132.48140.42121.82104.777.7488133.2130.7113.36165.87104.67114.83
Short-Term Debt12.69M9.35M10.17M5.71M4.89M4.27M10.18M5.98M5.21M4.03M2.18M3.02M2.24M2.3M2.3M9.02M3.94M4.52M2.81M2.25M2.6M2.2M1.63M1.21M1.85M1.8M2.48M2.45M3.58M454.55K
Deferred Revenue (Current)28.64M7.1M6.88M4.47M4.32M3.88M3.3M2.12M2.21M2.76M1.98M1.6M1.1M826K885K418K578K558K704K452.67K669.04K770.01K842.43K2.32M1.13M966.56K798.55K000
Other Current Liabilities16.06M7.53M8.04M6.85M5.79M4.63M4.83M3.72M3.77M4.14M4.4M3.72M1.82M1.44M1.2M3.31M837K824K771K834.64K1.21M1.06M936.12K1.3M2.63M1.01M2.51M6.65M6.65M7.82M
Current Ratio2.63x1.54x1.85x2.84x4.17x3.75x2.11x2.41x2.40x2.45x2.70x2.03x2.18x1.91x1.88x1.31x2.04x2.19x2.48x2.80x2.42x2.31x2.66x2.35x3.48x3.85x3.92x1.71x2.46x3.03x
Quick Ratio2.40x1.19x1.36x2.30x3.63x3.34x1.74x1.94x1.97x2.04x2.16x1.65x1.70x1.51x1.56x1.12x1.77x1.94x2.20x2.47x2.07x1.86x2.19x1.87x2.81x3.38x3.37x1.10x1.82x2.49x
Cash Conversion Cycle95.8125.91165.29158.88162.12123.81154.4135.23134.75142.13135.5122.63120.39124.14119.76179.47237.69220.86219.14175.71189.09195.94162.35244.94279.86168.82146.35341.32401.23238.79
Total Non-Current Liabilities38.71M22.44M7.62M7.77M8.31M10.49M7.76M8.02M6.77M5.48M7.27M7.88M4.86M6M9.16M3.14M12.38M12.62M12.21M17.65M2.25M1.55M1.66M1.93M1.61M2.29M5.44M7M6.91M3.73M
Long-Term Debt615K15.9M2.24M2.21M3.83M5.61M1.4M1.07M1.53M1M405.02K592K342K239K4.83M720K8.79M9.33M9.05M11.69M58.34K54.88K07.15K95.3K304.58K3.16M6.36M5.54M1.55M
Capital Lease Obligations5.61M2.43M2.01M1.45M1.31M1.5M2.02M2.67M973.96K634.02K330.14K294K355K378K494K695K961K1.37M1.31M1.03M696.32K473.66K662.44K579.64K0229.28K332.2K000
Deferred Tax Liabilities000000000006.49M4.08M5.34M3.75M01.29M808K447K006.75K000000426.33K545.45K
Other Non-Current Liabilities38.09M3.14M3M3.4M2.89M2.88M3.21M2.8M3.16M3.17M6.18M505K75K48K2K1.47M1.05M784K822K4.21M1.49M1.01M1M1.35M1.51M1.76M1.95M636.03K937.93K1.64M
Total Liabilities74.78M59.58M46.77M38.25M31.47M30.9M34.07M27.66M25.99M24.86M23.1M24.15M17.01M17.59M22.28M23.84M27.04M27.8M26.67M30.55M13.17M11.42M9.93M12.93M11.42M14.23M15.65M20.99M20.46M17.09M
Total Debt13.3M27.68M14.41M9.37M10.02M11.38M13.6M9.72M7.71M5.67M2.91M4.15M3.16M3.1M8.09M12.96M14.38M16.06M13.88M14.92M3.35M2.73M2.29M1.8M1.95M2.33M5.97M8.81M9.12M2M
Net Debt-42.97M7.23M-16.48M-38.65M-57.36M-42.28M-16.62M-13.72M-14.54M-18.36M-20.28M-9.43M-7.99M-3.58M1.04M8.06M7.01M4.47M58K-2.63M-6.54M-5.58M-7.1M-8.61M-13.82M-17.06M2.57M5.54M341.06K-9.73M
Debt / Equity0.37x1.43x0.34x0.15x0.13x0.20x0.42x0.32x0.27x0.19x0.11x0.29x0.21x0.33x0.99x1.49x1.62x1.28x0.81x1.03x0.17x0.16x0.13x0.09x0.07x0.06x0.17x0.57x0.37x0.06x
Debt / EBITDA-0.46x-----6.62x2.65x--1.86x2.78x----2.85x3.21x2.14x2.77x0.77x1.08x1.22x0.20x0.33x0.37x1.17x-1.19x3.14x
Net Debt / EBITDA1.50x------8.09x-3.74x---12.95x-6.33x----1.39x0.89x0.01x-0.49x-1.50x-2.21x-3.78x-0.95x-2.34x-2.74x0.51x-0.04x-15.29x
Interest Coverage-3.96x-35.98x-80.30x-89.28x-14.93x6.31x-3.77x7.25x-18.02x-46.07x6.86x-11.88x-5.09x-1.48x-2.56x0.38x-4.51x-4.29x2.17x-13.74x----------
Total Equity35.94M19.41M42.35M62.88M76.45M56.92M32.12M30.71M28.54M30.21M25.79M14.43M15.14M9.28M8.16M8.71M8.9M12.58M17.19M14.52M19.3M17.36M17.95M18.93M28.4M38.98M34.78M15.47M24.9M33.82M
Equity Growth %-205.6%-54.16%-32.65%-17.75%34.31%77.24%4.58%7.61%-5.54%17.14%--4.7%63.09%13.76%-6.34%-2.1%-29.25%-26.83%18.38%-24.76%11.18%-3.3%-5.16%-33.35%-27.14%12.08%124.8%-37.87%-26.38%-
Book Value per Share0.840.521.141.702.221.761.101.040.981.040.880.580.640.450.460.650.681.191.781.582.022.072.222.423.634.914.211.982.995.07
Total Shareholders' Equity35.94M19.41M42.35M62.88M76.45M56.92M32.12M30.71M28.54M30.21M25.79M14.43M15.14M9.28M8.16M8.71M8.9M12.58M17.19M14.52M19.3M17.36M17.95M18.93M28.4M38.98M34.78M15.47M24.9M33.82M
Common Stock7.53M6.07M5.06M5.36M5.1M4.99M4.69M4.29M4.36M4.58M3.99M3.35M3.28M2.88M2.44M1.78M1.74M1.42M1.3M1.25M1.21M1.09M1.09M1.09M1.09M1.08M1.02M1.06M1.02M0
Retained Earnings-156.65M-128.62M-85.5M-70.2M-45.22M-44.85M-49.11M-43.14M-45.67M-47.56M-41.06M-42.77M-41.1M-40.59M-35.57M-28.09M-27.15M-14.44M-6.67M-8.28M-2.84M596.93K1.66M2.81M11.8M15.85M8.78M-1.62M7.25M14.27M
Treasury Stock0-1.02M-828.4K-883.72K-957.32K-1.06M-1.14M-1.04M-1.31M-1.37M-1.2M-1.14M-1.17M-1.17M-1.17M-1.17M-1.17M-1.23M-1.3M-1.3M-3.02M-1.79M-1.8M-1.79M-1.8M-1.8M-1.73M-3.11M-3.07M0
Accumulated OCI0-8.34M-5.07M-4.96M-4.09M-4.08M-3.75M-3.86M-4.28M-4.33M-4.17M-3.57M-3.21M-3.22M-3.33M-3.59M-3.39M-3.13M-3.29M-3.09M-1.54M-2.87M-2.98M-2.95M-2.51M3.99M6.84M-732.42K-170.53K-5M
Minority Interest000000000000000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityWeak
Balance SheetVulnerable
Cash FlowDeteriorating
Top Statement Risk

Negative equity amid debt surge and cash depletion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Balance Sheet Erosion Accelerates Sharply

EDAP's balance sheet has deteriorated from a net asset position of $53.0M in 2024Q1 to negative equity of -$3.2M by 2026Q2, a swing of over $56M in roughly two years that appears driven by persistent losses and a dramatic increase in borrowing, based on EDAP's reported balance sheets.

Total liabilities rose from $36.1M to $77.8M over the same window while total assets fell from $89.1M to $74.5M, meaning the company is simultaneously accumulating obligations against a shrinking asset base. The cumulative retained earnings deficit of -$152.2M confirms that losses, not one-off charges, are the primary driver. This trajectory, if sustained, raises questions about the company's ability to continue operating as a going concern without external capital.

Debt Surge Signals Strategic or Survival Borrowing

Total debt exploded from $2.3M in 2026Q1 to $41.7M in 2026Q2, an 18-fold sequential increase that has pushed the debt-to-equity ratio to unmeasurable territory given negative equity, representing the single largest structural shift on EDAP's balance sheet in the ten-quarter record.

Prior to this spike, leverage had been modest at $5–9M for most of the period, so the Q2 borrowing appears to be a recent and potentially urgent financing event rather than a gradual strategic levering. With equity now negative, traditional leverage metrics break down, and investors should closely examine the terms, maturities, and covenants attached to this debt. The fact that this borrowing coincided with a quarter of sharply declining revenue and a 56.9% top-line contraction, as noted in the income statement analysis, suggests the financing may have been driven by liquidity necessity rather than opportunistic investment.

Accumulated Deficit Consumes Entire Equity Base

EDAP's equity turned negative at -$3.2M in 2026Q2, with retained earnings at -$152.2M, meaning cumulative losses have not only wiped out the original $53.0M equity base but have created a hole that exceeds reported total assets by a significant margin, as shown in EDAP's balance sheet.

The equity erosion has been relentless: from $53.0M in 2024Q1 through $40.9M in 2024Q4 to $19.4M by 2025Q4, before collapsing to negative territory. No share repurchases or dilutive equity issuances are evident in the data to offset this drawdown. For a medical device company in a competitive peer set where even loss-making peers like Novocure maintain positive equity of $1.6B market cap with 2.90x current ratio, EDAP's equity position appears exceptionally fragile.

Cash Decline and Ratio Compression Raise Near-Term Concerns

Cash fell from $38.4M in 2024Q1 to $11.8M in 2026Q2, a 69% drawdown, while the current ratio compressed from 2.62 to 1.60, suggesting the liquidity buffer that once provided comfortable runway has materially narrowed, according to EDAP's quarterly balance sheets.

The current ratio of 1.60, while still above 1.0, masks the quality of the underlying current assets given that cash represents only $11.8M against $41.7M of total debt, implying the company is increasingly dependent on debt to fund operations rather than internal liquidity. Working capital swings contributed temporary cash relief in recent quarters per the cash flow analysis, but these appear to be one-time inventory or receivable adjustments rather than sustainable sources. At the current burn trajectory of roughly $3–4M per quarter in operating cash outflow, the cash runway appears to be measured in quarters, not years.

Deferred Revenue Collapse Signals Order Pipeline Weakness

Deferred revenue plunged from $7.8M in 2026Q1 to just $923K in 2026Q2, an 88% sequential decline and the lowest level in the ten-quarter record, which may indicate a severe deterioration in contracted but unrecognized revenue and therefore future top-line visibility.

Deferred revenue is a leading indicator for medical device companies, representing committed customer obligations that convert to revenue over time. Its collapse to below $1M, when read alongside the 56.9% revenue decline in the same quarter, paints a consistent picture of demand deterioration that appears unlikely to reverse quickly. The prior stability of this metric in the $5–8M range for multiple quarters makes the Q2 drop appear anomalous and warrants investigation into whether large contracts were cancelled, restructured, or whether there was an accounting reclassification.

Asset Write-Downs Mask Potential Structural Impairment

PPE collapsed from $13.0M to $0 and goodwill fell from $2.8M to $735K between 2026Q1 and 2026Q2, a simultaneous elimination of both tangible and intangible assets that may signal significant impairment charges rather than routine asset disposal, based on EDAP's reported balance sheets.

For a manufacturing medical device company to report zero net PPE is highly unusual and could indicate either a complete write-down of production assets, a classification change, or the sale of manufacturing capability. Combined with the goodwill impairment, these asset reductions appear to contribute to the $15.7M drop in total assets between Q1 and Q2. This pattern warrants careful scrutiny because impairment charges reduce equity without affecting cash flow directly, meaning the headline equity deterioration may be partly non-cash, yet it also implies management no longer sees recoverable value in assets it previously carried.

FOCL — Frequently Asked Questions

Quick answers to the most common questions about buying FOCL stock.

What are the total assets of EDAP TMS S.A. American Depositary Shares (FOCL)?

As of 2025, EDAP TMS S.A. American Depositary Shares (FOCL) had total assets of $79.0M including $57.2M in current assets.

How much debt does EDAP TMS S.A. American Depositary Shares (FOCL) have?

EDAP TMS S.A. American Depositary Shares (FOCL) carries total debt of $27.7M, offset by $20.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of EDAP TMS S.A. American Depositary Shares?

EDAP TMS S.A. American Depositary Shares (FOCL) has total shareholders' equity (book value) of $19.4M ($0.52 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is EDAP TMS S.A. American Depositary Shares's current ratio and liquidity?

EDAP TMS S.A. American Depositary Shares (FOCL) reported a current ratio of 1.54x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.